Industry News

News

TEL：+86-21-33585366（DDT）
     34666753、33588661
FAX：+86-21-34979012
Q Q：  2762556331（Domestic）
      3501899018（Export）
E-mail：info@shyrchem.com
Domestic：sales@shyrchem.com
Export：sales02@shyrchem.com

Your current location：Home > News > Industry News

The National Health Insurance Bureau responded that Pfizer COVID-19's therapeutic drugs were not in 2023-01-12
Novo Nordisk Shanghai and Shanghai Pharmaceutical Holding will make another breakthrough in signing 2022-12-09
Review of clinical application of new drugs in the first half of the year: anti-tumor drugs are the 2022-11-28
Why are epidemic prevention and control measures adjusted? The latest interpretation is coming 2022-11-14
China Center for Disease Control and prevention: the five major branches of novel coronavirus are no 2022-09-19
The global pharmaceutical industry chain is reshaping, and China's API industry is stable and far-r 2022-08-16
Although China's generic drugs started late, the future can be expected 2022-08-05
Good API industry attracts investors' attention 2021-03-19
How to ensure the safety of the world's top P4 biological laboratory? 2021-02-24
What is biosafety laboratory? 2021-01-07

Pages：1/2 page18 total30 home last next end go to:

Copyright © 2017-2020 SHANGHAI YINGRUI BIOPHARMA CO.,LTD 沪ICP备11038445号-1
TEL：+86-21-33585366(DDT)、34666753 FAX：+86-21-34979012
E-mail：info@shyrchem.com ADD：1885 Metropolitan Road, Minhang District, Shanghai Code：201108